These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1431345)

  • 21. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
    Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinical relevance of anti-CEA immunoscintigraphy with the 99mTc-labelled monoclonal antibody BW 431/26. A critical assessment after 119 studies].
    Hach A; Wittig B; Piepenburg R; Steinert H; Lahmann C; Dippold W; Hahn K
    Rofo; 1992 Jul; 157(1):3-10. PubMed ID: 1638001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Radioimmunotargeting: diagnosis and therapeutic use].
    Vuillez JP
    Bull Cancer; 2000 Nov; 87(11):813-27. PubMed ID: 11125290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography.
    Buccheri G; Biggi A; Ferrigno D; Leone A; Taviani M; Quaranta M
    Chest; 1993 Sep; 104(3):734-42. PubMed ID: 8365283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoscintigraphy with 99Tcm-labelled monoclonal anti-CEA BW 431/26 antibodies in patients with suspected recurrent and metastatic colorectal carcinoma: two-year follow-up.
    Lacić M; Bokulić T; Lukac J; Baum RP; Kusić Z
    Nucl Med Commun; 1999 Sep; 20(9):859-65. PubMed ID: 10533193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
    Ychou M; Azria D; Menkarios C; Faurous P; Quenet F; Saint-Aubert B; Rouanet P; Pèlegrin M; Bascoul-Mollevi C; Guerreau D; Saccavini JC; Mach JP; Artus JC; Pèlegrin A
    Clin Cancer Res; 2008 Jun; 14(11):3487-93. PubMed ID: 18519781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoscintigraphy using 111in-labelled F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of non-small cell lung carcinoma.
    Vuillez JP; Moro D; Brambilla E; Brichon PY; Ferretti G; Saccavini JC; Brambilla C
    Eur J Cancer; 1994; 30A(8):1089-92. PubMed ID: 7654435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and role of repeated administrations of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the postoperative follow-up of colorectal carcinoma patients.
    Abdel-Nabi HH; Doerr RJ; Chan HW; Farrell E; Evans NH; Spaulding MB; Schweighardt S; Merchant EB
    J Nucl Med; 1992 Jan; 33(1):14-22. PubMed ID: 1730980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
    Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass.
    Williams LE; Bares RB; Fass J; Hauptmann S; Schumpelick V; Buell U
    Eur J Nucl Med; 1993 Apr; 20(4):345-7. PubMed ID: 8491228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CEA and other antibodies in the study of gastrointestinal tumors.
    Lastoria S; Caracò C; Vergara E; Castelli L; Salvatore M
    Int J Biol Markers; 1992; 7(3):198-202. PubMed ID: 1431346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.
    Paganelli G; Magnani P; Zito F; Villa E; Sudati F; Lopalco L; Rossetti C; Malcovati M; Chiolerio F; Seccamani E
    Cancer Res; 1991 Nov; 51(21):5960-6. PubMed ID: 1933860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Radioimmunodetection of colorectal cancer, using anti-CEA monoclonal antibody CEA102: experience of 20 cases].
    Murakami K; Watanabe T; Tadokoro M; Sakamoto J; Murayama H; Wada K; Sakuma S; Takagi H
    Nihon Geka Gakkai Zasshi; 1993 Feb; 94(2):119-27. PubMed ID: 8464409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14.
    Sharkey RM; Goldenberg DM; Murthy S; Pinsky H; Vagg R; Pawlyk D; Siegel JA; Wong GY; Gascon P; Izon DO
    Cancer; 1993 Mar; 71(6):2082-96. PubMed ID: 8443758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
    Zhu H; Jain RK; Baxter LT
    J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunodetection of cancer using antibodies to alpha-fetoprotein and carcinoembryonic antigen.
    Ishii N; Nakata K; Muro T; Furukawa R; Kono K; Kusumoto Y; Munehisa T; Koji T; Nagataki S; Nishi S
    Ann N Y Acad Sci; 1983; 417():270-6. PubMed ID: 6200035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BIS-1: a novel bispecific monoclonal antibody for CEA-expressing carcinoma radioimmunoscintigraphy and radioimmunotherapy.
    Parisi A; Bartolazzi A; Bonino C; Camagna M; DeMonte LB; Lombardi A; Natali PG; Paganelli G; Tarditi L; Vassarotto C
    Year Immunol; 1993; 7():96-105. PubMed ID: 8372516
    [No Abstract]   [Full Text] [Related]  

  • 40. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
    Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
    Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.